financetom
Business
financetom
/
Business
/
S&P Assigns Rating to Dye & Durham; Down Nearly 1%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
S&P Assigns Rating to Dye & Durham; Down Nearly 1%
Mar 22, 2024 7:54 AM

10:31 AM EDT, 03/22/2024 (MT Newswires) -- S&P Global Ratings said Thursday that it has assigned its B issuer credit rating to Dye & Durham Ltd. ( DYNDF ) .

This reflects its relatively small scale, operations in a niche segment of the legal industry, adjusted debt-to-EBITDA of about 6.3x, and concentrated ownership while acknowledging the company's diverse customer base and track record of high margins and steady free cash flow generation, the rating agency said.

At the same time, the agency assigned its B issue-level rating to the company's proposed $495 million of seven-year senior secured term loan B and $680 million of other secured debt.

"The stable outlook reflects our expectations that the company's revenues and EBITDA will benefit from increasing transaction volumes as well as growing annual recurring revenue (ARR). The rating also captures management's ambitious growth strategy," S&P said.

The company's stock slipped nearly 1% on last look on Friday.

Price: 15.43, Change: -0.19, Percent Change: -1.22

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Invivyd's Covid Treatment for Immunodeficiency Disorders Gets FDA Nod; Shares Up Before Trading Halt
Invivyd's Covid Treatment for Immunodeficiency Disorders Gets FDA Nod; Shares Up Before Trading Halt
Mar 22, 2024
03:57 PM EDT, 03/22/2024 (MT Newswires) -- Invivyd ( IVVD ) stock was up 4.5% Friday before its trading was halted to announce an emergency use authorization for its Pemgarda monoclonal antibody to prevent COVID-19 in adults and youths with moderate-to-severe immunodeficiency disorders. The US Food and Drug Administration decision makes Pemgarda available to people 12 years or older with...
Update: Market Chatter: Ares Management, KKR Looking to Take Over Barings' Investments Following Exodus
Update: Market Chatter: Ares Management, KKR Looking to Take Over Barings' Investments Following Exodus
Mar 22, 2024
03:56 PM EDT, 03/22/2024 (MT Newswires) -- (Updates with Ares and KKR declining to comment in fifth paragraph.) Ares Management ( ARES ) , KKR (KKR) and other private credit firms are keen to take advantage of troubles at Barings after more than 20 of its senior executives moved to Corinthia Global Management earlier this month, Bloomberg reported Friday. The...
UnitedHealth's Change to start processing $14 billion in medical claims as services come online
UnitedHealth's Change to start processing $14 billion in medical claims as services come online
Mar 22, 2024
(Reuters) -UnitedHealth Group ( UNH ) said on Friday it expects more than $14 billion in medical claims to start flowing soon through its unit Change Healthcare as several services for handling them gradually come online over the next few weeks following a hack last month. The health insurer said its software for preparing medical claims Assurance went online on...
Anthropic weighs slate of sovereign wealth funds to acquire FTX's $1 bln stake, CNBC reports
Anthropic weighs slate of sovereign wealth funds to acquire FTX's $1 bln stake, CNBC reports
Mar 22, 2024
March 22 (Reuters) - Anthropic, backed by Google and Amazon.com ( AMZN ), is weighing a slate of sovereign wealth funds to acquire FTX's stake of about $1 billion in the AI startup, CNBC reported on Friday citing sources. In February, a U.S. judge ruled that bankrupt crypto exchange FTX may sell its shares in Anthropic. FTX invested $500 million...
Copyright 2023-2025 - www.financetom.com All Rights Reserved